Alexis A. Thompson, MD, MPH, Considers Future Assessments of Beti-Cel in β-Thalassemia
Alexis A. Thompson, MD, MPH, reviewed the unmet needs of patients with β-thalassemia who will receive betibeglogene autotemcel.
Optimizing Molecular Testing in Patients With Non-Small Cell Lung Cancer
Closing out their discussion on NSCLC biomarker testing assay selection, panelists consider the optimal use of these assays in their own patients.
Molecular Testing Assays in Non-Small Cell Lung Cancer
Expert oncologists provide a comprehensive review of available biomarker testing assays utilized in patients diagnosed with non–small cell lung cancer.
Rafael Fonseca, MD, Talks Future of Multiple Myeloma With Off-the-Shelf Cellular Therapies
Rafael Fonseca, MD, spoke about how bispecific antibodies like elranatamab have the potential to change the treatment paradigm for patients with relapsed/refractory multiple myeloma.
Selecting the Appropriate Patients and Monitoring Responses to CAR T-Cell Therapy in LBCL
Dr Lori Leslie discusses how to assess if a patient with large B-cell lymphoma is a good candidate for CAR T-cell therapy.
Clinical Trial and Real-World Evidence Around CAR T-cell Therapy in LBCL
Andrew Ip, MD, and Lori Leslie, MD, review clinical trial and real-world data on the efficacy and survival rates of CAR T-cell therapy in large B-cell lymphoma.
Phillip H. Kuo, MD, PhD, Reviews Rationale of Phase 3 VISION Trial of 177Lu-PSMA-617 in mCRPC
Phillip H. Kuo, MD, PhD, spoke about the use of theragnostic treatment and imaging for patients with metastatic castration-resistant prostate cancer.
Treatment Decision-Making Based on Real-World Data in Transplant-Ineligible NDMM
Dr Rafael Fonesca illustrates how he selects therapies for patients with transplant-ineligible multiple myeloma based on real-world evidence.
Triplet vs Doublet Induction Therapy for Transplant-Ineligible MM and Role of Real-World Evidence
A key opinion leader explains whether doublet regimens still have a place in transplant-ineligible multiple myeloma treatment.
Selecting Therapy for Low-Volume mCSPC
Panelists provide comprehensive insight on treatment strategies specific to the setting of low-volume metastatic prostate cancer.
Metastatic CSPC: Rationale Behind ADT + Apalutamide Therapy
Expert oncologists review the selection of apalutamide + androgen deprivation therapy in this patient scenario of metastatic castration-sensitive prostate cancer.
Circulating Tumor DNA: Future Directions in Care
Expert oncologists look toward future utilization of circulating tumor DNA testing and consider how the field of oncology may evolve.
Considering Real-World Applications With ctDNA
Shared insight on how circulating tumor DNA may be used in real-world clinical practice to improve the value of cancer care.
Scenario 1: A 44-Year-Old Man With Acute Graft vs Host Disease
Centering discussion on a scenario of acute graft vs host disease, expert panelists consider optimal workup of a patient showing signs of GVHD.
Understanding the Pathophysiology of Acute vs Chronic GVHD
Shared insight on the pathophysiology of graft vs host disease, with specific regard for differences between acute GVHD vs chronic GVHD.
Trevor M. Feinstein, MD, Reviews QOL Analysis of DUBLIN-3 Trial Comparing Docetaxel With or Without Plinabulin in NSCLC
Trevor M. Feinstein, MD, spoke about how quality of life was improved for patients with EGFR wild-type stage IIIB/IV non–small cell lung cancer receiving plinabulin in addition to docetaxel the phase 3 DUBLIN-3 trial.
Angela DeMichele, MD, MSCE, Assesses the Value of I-SPY2 for Neoadjuvant Treatment of Early Breast Cancer
Angela DeMichele, MD, MSCE, spoke about the I-SPY2 trial, which evaluates patients with early breast cancer who are treated with experimental neoadjuvant systemic therapy regimens.
Alexis A. Thompson, MD, MPH, Assesses the Need for Beti-Cel in β-Thalassemia
Alexis A. Thompson, MD, MPH, reviewed unmet needs for patients with β-thalassemia who may now receive betibeglogene autotemcel.
Tanios S. Bekaii-Saab, MD, on Using Assays to Predict Outcomes and Select Adjuvant Therapy in Stage II CRC
Data from the phase 2 DYNAMIC trial show that a circulating tumor DNA–guided approach to adjuvant therapy selection may be feasible for patients with stage II colorectal cancer, but Tanios S. Bekaii-Saab, MD, is skeptical about its readiness for prime time.
Paul G. Richardson, MD, Considers How Data Surrounding Standard Triplet Therapies in Myeloma Inform Use of Newer Regimens
Paul G. Richardson, MD, presented data from the phase 3 DETERMINATION study at 2022 ASCO and theorized how these findings could extend to similar regimens in newly diagnosed multiple myeloma.
